TEL-AVIV, Israel, Dec. 21, 2016 (GLOBE NEWSWIRE) -- RedHill
Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a
biopharmaceutical company primarily focused on the development and commercialization
of late clinical-stage, proprietary, orally-administered, small molecule drugs
for gastrointestinal and inflammatory diseases and cancer, today announced that
it intends to offer its American Depositary Shares (“ADSs”), each representing
ten of its ordinary shares, and warrants to purchase ADSs, concurrently in an
underwritten public offering and in a registered direct offering. RedHill also
expects to grant the underwriters a 30-day option to purchase up to an
additional 15% of the securities offered to the public in the underwritten
public offering. Both offerings are subject to market conditions and there can
be no assurance as to whether or when the offerings may be completed, or as to
the actual size or terms of the offerings.
Source : RedHill Biopharma Ltd.
No comments:
Post a Comment